Skip to content
Screener

Lantheus Holdings LNTH Definity — Revenue

Other product segments

Oncology
$240.37M—
PYLARIFY
$240.37M-4.1%
Cardiology
$88.28M—
Neuraceq
$39.62M—
Neurology
$39.62M—
Strategic Partnerships And Other
$19.92M+71.9%
Licenseand Royalty Revenues
$11.25M+222%
SPECT Business
$0—

Similar metrics at other companies

Lennar logo
LENOther revenues — Revenue
$331.4M-6.8%
HRO
HROWOther Revenues — Revenue
$73K-15.1%
PROG Holdings logo
PRGOther Revenues — Revenue
$21.62M+165%
Oracle logo
ORCLCloud Revenues — Revenue
$9.91B+47.1%
Oracle logo
ORCLSoftware Revenues — Revenue
$6.82B-2.1%
Blue Owl Capital logo
OWLPerformance revenues — Revenue
$6.07M-3.9%

Other financials

Income statement

See full
Revenue$388.2M+2.7%
Gross profit$241.9M+0.4%
Operating income$100.2M+13.9%
Net income$75.0M-4.7%
EPS (diluted)$1.11-0.9%

Balance sheet

See full
Cash & equivalents$595.0M-14.7%
Total debt$626.8M+1.5%
Total equity$1.3B+12.4%
Total assets$2.4B+14.1%

Cash flow

See full
Operating cash flow$92.2M+5.9%
CapEx$2.3M-70.7%
Free cash flow$89.9M+13.5%

Valuation

See full
Market cap$6.63B+84.6%
Enterprise value$6.66B+89.7%
P/E24.1×+11.4×
P/S4.3×+1.9×

Profitability

See full
Gross margin60.1%-3.6pp
Operating margin19.4%-9.4pp
Net margin17.7%-0.9pp
FCF margin24.9%-6.6pp

Returns & leverage

See full
Return on equity22.2%-3.6pp
Debt / equity0.5×-0.1×
Current ratio3.1×-1.2×

Where this comes from

Reported directly by Lantheus Holdings in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Lantheus Holdings’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 8:01 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-336795
(in thousands)Three Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Total oncology240,366250,642481,290508,296
Neuraceq39,616—75,055—
Total neurology39,616—75,055—
DEFINITY88,27983,939172,906163,150
Total cardiology88,27983,939172,906163,150
Strategic partnerships and other19,91911,59036,26222,337
SPECT—31,874—57,026
Total revenues$388,180$378,045$765,513$750,809

Item 1. Financial Statements

FAQ

What is Lantheus Holdings's definity — revenue?
Lantheus Holdings (LNTH) reported definity — revenue of $88.28M in Q2 2026.
How has Lantheus Holdings's definity — revenue changed year-over-year?
Lantheus Holdings's definity — revenue increased by 5.2% year-over-year, from $83.94M to $88.28M.
What is the long-term trend for Lantheus Holdings's definity — revenue?
Over 4 years (2021 to 2025), Lantheus Holdings's definity — revenue has grown at a 9.1% compound annual growth rate (CAGR), from $232.76M to $330.25M.
What does definity — revenue mean?
This metric represents the total gross revenue generated from the sale of a specific diagnostic product line, net of any assessed taxes. It serves as a primary indicator of market demand and commercial adoption for the company's core diagnostic offerings. Tracking this figure allows investors to assess the growth trajectory and revenue contribution of the product segment relative to the company's total portfolio.

Ask your AI about Lantheus Holdings's definity — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude